Major Depressive Disorder Clinical Trial
Official title:
A Randomized, Double-blind, Placebo Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Venlafaxine Er In Adult Outpatients With Major Depressive Disorder
NCT number | NCT01441440 |
Other study ID # | B2411263 |
Secondary ID | |
Status | Completed |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | November 2011 |
Est. completion date | March 2014 |
Verified date | March 2015 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of venlafaxine ER 75 mg/day (fixed dose) and venlafaxine ER 75 mg/day to 225 mg/day (flexible dose), compared to placebo. This study consists of 2 week screening phase, 8 week treatment phase and 2 week tapering phase. The follow-up visit will be evaluated after 2 weeks of last study medication dosing.
Status | Completed |
Enrollment | 538 |
Est. completion date | March 2014 |
Est. primary completion date | March 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility | Inclusion Criteria: - Outpatient status. - A primary diagnosis of MDD based on the criteria in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM- IV-TR), single or recurrent episode, without psychotic features. - Depressive symptoms for at least 90 days in single episode and for at least 28 days in recurrent episode before the screening visit. - A MADRS total score =26 at the screening and baseline visits. And change of MADRS total score at baseline is not over 25% from the screening visit. - A QIDS16-J-SR score =16 at the screening and baseline visits. - A score =4 on the Clinical Global Impressions Scale-Severity (CGI-S) at the screening and baseline visits. Exclusion Criteria: - Subjects who concurrently have Axis II personality disorder or mental retardation according to DSM-IV diagnostic criteria. - Subjects who meet DSM-IV criteria for current or past history of Schizophrenia, Paranoid Disorders, or any other Psychotic Disorders. - Subjects who meet DSM-IV criteria for current or past history of Dementia. - Subjects who meet DSM-IV criteria for current or past history of bipolar disorder, Posttraumatic Stress Disorder (PTSD) or Obsessive Compulsive Disorder (OCD). - Subjects who meet DSM-IV criteria for current (within 12 months before the screening visit) generalized anxiety disorder, panic disorder, or social anxiety disorder considered by the investigator to be primary (causing a higher degree of distress or impairment than MDD). - Subjects with a first degree relative with bipolar disorder. - Subjects who are actively suicidal. - History of non-responsive to 2 antidepressant treatment (at least 6-week usage for each) for the past or current episodes. - History of Electroconvulsive therapy (ECT) at any time in the past. - History of chronic treatment with benzodiazepines for longer than 6 months before the screening visit (Excluding subjects who have taken PRN benzodiazepine use, < 3 times/week). - Any unstable hepatic, renal, pulmonary, cardiovascular (including uncontrolled hypertension), ophthalmologic, neurologic, or any other medical condition that in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and completion of, the study. - Known presence of raised intraocular pressure or history or presence of narrow angle glaucoma. - Myocardial infarction within 180 days of the screening visit. - Clinically important abnormalities, as determined by the investigator, on screening physical examination, electrocardiogram (ECG) or laboratory tests. - Use of prohibited treatments |
Country | Name | City | State |
---|---|---|---|
Japan | Suzuki Hospital | Adachi-ku | Tokyo |
Japan | Arai Clinic | Amagasaki | Hyogo |
Japan | Takahashi Psychiatric Clinic | Ashiya | Hyogo |
Japan | Iidabashi Mental Clinic | Chiyoda-ku | Tokyo |
Japan | Tutujigaoka Mental Clinic | Chofu | Tokyo |
Japan | Akasaka Kato Clinic | Fukuoka | |
Japan | Ange Psychiatric Clinic | Fukuoka | |
Japan | Hiro Mental Clinic Tenjinminami | Fukuoka | |
Japan | Imato Clinic | Fukuoka | |
Japan | Kuranari Psychiatry Clinic | Fukuoka | |
Japan | Medical Corporation Shinseikai Kaku Mental Clinic | Fukuoka | |
Japan | Stress Care Yoshimura Clinic | Fukuoka | |
Japan | Sugahara Tenjin Clinic | Fukuoka | |
Japan | Tenjin Mental Clinic | Fukuoka | |
Japan | Hatsuki Shinryo Clinic | Fukuoka-city | Fukuoka |
Japan | Fujikawa Clinic | Hatsukaichi | Hiroshima |
Japan | Kuginuki Clinic | Hirakata | Osaka |
Japan | Tsuji Mental Clinic | Hiroshima | |
Japan | Nippon Medical School Chiba Hokusoh Hospital | Inzai | Chiba |
Japan | Medical Corporation Toyokokai Tawara Clinic | Kanagawa | |
Japan | National Hospital Organization Kanazawa Medical Center | Kanazawa | Ishikawa |
Japan | Fuku Clinic | Katsushika-ku | Tokyo |
Japan | Medical Corporation Seishinkai Kishiro Mental Clinic | Kawasaki | Kanagawa |
Japan | Hatakeyama Clinic | Kitakyushu-shi | Fukuoka |
Japan | Ikeuchi Psycho Induced Internal Med.Clinic | Kobe | Hyogo |
Japan | Tatsuta Clinic | Kobe | Hyogo |
Japan | Yuge Hospital | Kumamoto-shi | Kumamoto |
Japan | Hayakawa Clinic | Kure | Hiroshima |
Japan | Sagaarashiyama-Tanaka Clinic | Kyoto | |
Japan | Akasaka Clinic | Minato-ku | Tokyo |
Japan | SAKURAZAKA CLINIC SophyAnce | Minato-ku | Tokyo |
Japan | Hida Clinic | Nagareyama | Chiba |
Japan | Mizuho Clinic | Nagoya | Aichi |
Japan | Narumi Himawari Clinic | Nagoya | Aichi |
Japan | Harikae mental clinic | Nakano-Ku | Tokyo |
Japan | Heartcare Ginga Clinic | Nakano-ku | Tokyo |
Japan | Kyo Mental Clinic | Nara | |
Japan | Nakamoto Clinic | Noda City | Chiba |
Japan | Shiranui Hospital | Omuta | Fukuoka |
Japan | Oka Clinic | Omuta-city | Fukuoka |
Japan | JIN clinic | Osaka | |
Japan | Shibamoto Clinic | Osakasayama-shi | Osaka |
Japan | Yutaka Clinic | Sagamihara | Kanagawa |
Japan | Misato Ekimae Clinic | Saitama | |
Japan | Sakai Mental Clinic | Saitama-city | Saitama |
Japan | Kawamura Mental Clinic | Sapporo | Hokkaido |
Japan | Maruyamapark Mentalclinic | Sapporo | Hokkaido |
Japan | Komazawa Mental Clinic | Setagaya-ku | Tokyo |
Japan | Sangenjaya Nakamura Mental Clinic | Setagaya-ku | Tokyo |
Japan | Maynds Tower Mental Clinic | Shibuya-ku | Tokyo |
Japan | Omotesando Mental Clinic | Shibuya-ku | Tokyo |
Japan | Yoyoginomori Mental Clinic | Shibuyaku | Tokyo |
Japan | Himeno Tomomi Clinic | Shinagawa-Ku | Tokyo |
Japan | Meguro sta.East Mental Clinic | Shinagawa-ku | Tokyo |
Japan | Kagurazaka Stress Clinic | Shinjuku-ku | Tokyo |
Japan | Nishi-Shinjuku Concieria Clinic | Shinjuku-ku | Tokyo |
Japan | Tamaki Clinic | Shinjuku-ku | Tokyo |
Japan | Tokyo Kosei Nenkin Hospital | Shinjuku-ku | Tokyo |
Japan | Tokyo Women's Medical University Hospital | Shinjuku-ku | Tokyo |
Japan | Eto Mental Clinic Meguro | Tokyo | |
Japan | Himorogi Psychiatric Institute | Toshima-ku | Tokyo |
Japan | Azamino Mental Clinic | Yokohama-Shi | Kanagawa |
Japan | Shioiri Mental Clinic | Yokosuka city | Kanagawa |
Lead Sponsor | Collaborator |
---|---|
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change From Baseline in 17-item Hamilton Raing Scale for Depression (HAM-D17) Total Score at Week 8 or Early Termination | HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression (symptoms such as depressed mood, work and activities, sleep, suicide, psychomotor agitation/retardation, appetite, sexual interest, anxiety, and somatic symptoms). The items of the HAM-D17 are rated on a scale of 0 to 2 or 0 to 4, and the total score ranges from 0 to 52. Higher scores indicate more severe symptoms. Change from baseline: mean score at Week 8 or early termination minus mean score at baseline. | Baseline, Week 8 or Early termination | |
Secondary | Changes From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8 or Early Termination | MADRS is a scale used in subjects with major depressive disorder to measure the overall severity of depressive symptoms. It is a 10 item, clinician-rated scale that assesses treatment-sensitive change by evaluating ten areas of depressive symptomatology: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts. The items are rated on a 7 point Likert scale (0 - 6) with anchors at 2 point intervals. The total score ranges from 0 to 60, and higher scores indicate more severe symptoms. Change from baseline: mean score at Week 8 or early termination minus mean score at baseline. | Baseline, Week 8 or Early termination | |
Secondary | Changes From Baseline in Clinical Global Impression-Severity (CGI-S) at Week 8 or Early Termination | CGI-S is a 7-point clinician rated scale to assess severity of participant's current illness state; range: 1=normal, not ill at all, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=among the most extremely ill patients. Higher scores reflect higher severity of current illness states. Change from baseline: mean score at Week 8 or early termination minus mean score at baseline. | Baseline, Week 8 or Early termination | |
Secondary | Changes From Baseline in 6-item Hamilton Rating Scale for Depression (HAM-D6) Total Score at Week 8 or Early Termination | HAM-D6 is a subset of the HAM-D17 that assesses 6 items associated with major depression. The scale uses HAM-D17 items 1, 2, 7, 8, 10 and 13. Item 13 is scored 0 to 2 and all others are scored 0 to 4. Total score ranges from 0 to 22; higher score indicates more depression. Change from baseline: mean score at Week 8 or early termination minus mean score at baseline. | Baseline, Week 8 or Early termination | |
Secondary | Changes From Baseline in 16-item Quick Inventory of Depressive Symptomatology Self-Report Japanese Version (QIDS16-SR-J) Total Score at Week 8 or Early Termination | QIDS16-SR-J is a self-rated scale used in patients with major depressive disorder to measure the overall severity of depressive symptoms: 1) sad mood; 2) concentration; 3) self-criticism; 4) suicidal ideation; 5) interest; 6) energy/fatigue; 7) sleep disturbance (initial, middle, and late insomnia or hypersomnia); 8) decrease/increase in appetite/weight; and 9) psychomotor agitation/retardation. QIDS16-SR-J items are rated on a scale of 0 to 3. The total score ranges from 0 to 27, and higher scores indicate more severe symptoms. Change from baseline: mean score at Week 8 or early termination minus mean score at baseline. | Baseline, Week 8 or Early termination | |
Secondary | Mean Clinical Global Impression - Improvement (CGI-I) Score at Week 8 or Early Termination | CGI-I is a 7-point clinician rated scale ranging from 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, to 7=very much worse. Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Scores above 4 reflect worsening of illness state as compared to baseline. | Baseline, Week 8 or Early termination |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |